NTRA ▼ -0.3% - Natera, Inc.
$NTRA - Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
05-OCT-2026 08:04 AM ET
Share this post
More filings for $NTRA
NTRA ▲ +0.2% - Natera, Inc.Nov 10, 2026NTRA - Natera, Inc. - SEC Filing Update (06-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 6, 2026NTRA ▼ -22.2% - Natera, Inc.Nov 5, 2026NTRA ▼ -28.3% - Natera, Inc.Nov 5, 2026NTRA ▼ -25.8% - Natera, Inc.Nov 5, 2026NTRA - Natera, Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026
View full $NTRA filing history →💬 Comments
Loading comments…
Leave a comment